Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Lisa A Kaltenbach"'
Autor:
Jennifer A. Rymer, Zachary K. Wegermann, Lisa A. Kaltenbach, Laura E. Webb, Eric D. Peterson, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 12 (2023)
Background Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving medication persistence. Current risk models have limited ability to predict patients at risk of P
Externí odkaz:
https://doaj.org/article/d273049689e64f5682de662939dbb918
Autor:
Jennifer A. Rymer, Lisa A. Kaltenbach, Eric D. Peterson, David J. Cohen, Gregg C. Fonarow, Niteesh K. Choudhry, Timothy D. Henry, Christopher P. Cannon, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 20 (2022)
Background Persistence to P2Y12 inhibitors after myocardial infarction (MI) remains low. Out‐of‐pocket cost is cited as a factor affecting medication compliance. We examined whether a copayment intervention affected 1‐year persistence to P2Y12
Externí odkaz:
https://doaj.org/article/c2bc639b139b4b899c96f8eda4705648
Autor:
Utibe R. Essien, Karen Chiswell, Lisa A. Kaltenbach, Tracy Y. Wang, Gregg C. Fonarow, Kevin L. Thomas, Mintu P. Turakhia, Emelia J. Benjamin, Fatima Rodriguez, Margaret C. Fang, Jared W. Magnani, Clyde W. Yancy, Jonathan P. Piccini
Publikováno v:
JAMA cardiology. 7(12)
ImportanceOral anticoagulation (OAC) is underprescribed in underrepresented racial and ethnic group individuals with atrial fibrillation (AF). Little is known of how differential OAC prescribing relates to inequities in AF outcomes.ObjectiveTo compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d957764810201e86fef4d1e8f0de98
https://pubmed.ncbi.nlm.nih.gov/36287545
https://pubmed.ncbi.nlm.nih.gov/36287545
Publikováno v:
American Heart Journal. 255:117-124
Appropriate use criteria (AUC) have been developed to promote the rational use of percutaneous coronary intervention (PCI) among clinicians and to provide benchmarking feedback to hospitals. The original AUC were published in 2012 and subsequently up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68283f607ebb02d3de97109af40799b6
https://doi.org/10.1016/j.ahj.2022.10.002
https://doi.org/10.1016/j.ahj.2022.10.002
Autor:
Jacob A. Doll, Lisa A. Kaltenbach, Kevin J. Anstrom, Christopher P. Cannon, Timothy D. Henry, Gregg C. Fonarow, Niteesh K. Choudhry, Eileen Fonseca, Narinder Bhalla, James M. Eudicone, Eric D. Peterson, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background Hospitals commonly provide a short‐term supply of free P2Y12 inhibitors at discharge after myocardial infarction, but it is unclear if these programs improve medication persistence and outcomes. The ARTEMIS (Affordability and Real‐Worl
Externí odkaz:
https://doaj.org/article/a86cb2e7179048ca8323fa7e3710c7ed
Autor:
VISHAL N. RAO, LISA A. KALTENBACH, BRADI B. GRANGER, GREGG C. FONAROW, HUSSEIN R. AL-KHALIDI, NANCY M. ALBERT, JAVED BUTLER, LARRY A. ALLEN, DAVID E. LANFEAR, DAN ARIELY, JULIE M. MILLER, MICHAEL A. BRODSKY, THOMAS A. LALONDE, JAMES C. LAFFERTY, CHRISTOPHER B. GRANGER, ADRIAN F. HERNANDEZ, ADAM D. DEVORE
Publikováno v:
Journal of Cardiac Failure. 28:1487-1496
It is unknown whether digital applications can improve guideline-directed medical therapy (GDMT) and outcomes in heart failure with reduced ejection fraction (HFrEF).Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3400d20928a2515c403fd967cb14936f
https://doi.org/10.1016/j.cardfail.2022.07.050
https://doi.org/10.1016/j.cardfail.2022.07.050
Autor:
BRADI B. Granger, LISA A. KALTENBACH, GREGG C. FONAROW, LARRY A. ALLEN, DAVID E. LANFEAR, NANCY M. ALBERT, HUSSEIN R. AL-KHALIDI, JAVED BUTLER, LAUREN B. COOPER, TRACY Dewald, G. MICHAEL Felker, PAUL HEIDENREICH, ANUPAMA KOTTAM, ELDRIN F. LEWIS, ILEANA L. PIÑA, CLYDE W. YANCY, CHRISTOPHER B. GRANGER, ADRIAN F. HERNANDEZ, ADAM D. DEVORE
Publikováno v:
Journal of Cardiac Failure. 28:1355-1361
Health system-level interventions to improve use of guideline-directed medical therapy (GDMT) often fail in the acute care setting. We sought to identify factors associated with high performance in adoption of GDMT among health systems in CONNECT-HF.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29a637c1d5f17b99e5d343e651a8c389
https://doi.org/10.1016/j.cardfail.2022.03.356
https://doi.org/10.1016/j.cardfail.2022.03.356
Autor:
Jennifer A. Rymer, Lisa A. Kaltenbach, Jacob A. Doll, John C. Messenger, Eric D. Peterson, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 10 (2019)
Background Although recommended in the guidelines, the safety of chronic P2Y12 inhibitor therapy in patients with chronic kidney disease (CKD) after an acute myocardial infarction (MI) is not well studied. Methods and Results The TRANSLATE‐ACS (Tre
Externí odkaz:
https://doaj.org/article/8a05cb4947b0401ba0650c152ccc4fa1
Autor:
Amneet Sandhu, Lisa A. Kaltenbach, Karen Chiswell, Vijay Shimoga, Carmel Ashur, Abby Pribish, Gregg C. Fonarow, Jonathan P. Piccini, P. Michael Ho, Paul D. Varosy, Paul L. Hess
IntroductionAmong patients hospitalized for atrial fibrillation (AF), the frequency of off-label direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and temporal trends in contemporary clinical practice are unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5683f0c904e5209b13df1f2a518064dc
https://doi.org/10.1101/2023.03.17.23287428
https://doi.org/10.1101/2023.03.17.23287428
Autor:
Alexander C. Fanaroff, Lisa A. Kaltenbach, Eric D. Peterson, Mohammed W. Akhter, Mark B. Effron, Timothy D. Henry, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 4 (2018)
BackgroundGuidelines recommend P2Y12 inhibitor therapy for 1 year after myocardial infarction (MI), yet little guidance is provided on antiplatelet management for patients with recurrent ischemic events during that year. We describe changes in P2Y12
Externí odkaz:
https://doaj.org/article/1b369de724e947e58a1b174e51c55584